Alkem Laboratories

Alkem Laboratories’ Alkem Laboratories Chakan manufacturing facility has been issued a Form 483 by the US Food and Drug Administration (USFDA) following an inspection, signaling observations of potential compliance gaps under current Good Manufacturing Practices (cGMP). While a Form 483 does not constitute enforcement action, it requires the company to respond with corrective measures. The development has drawn attention from investors and industry stakeholders, emphasizing the importance of regulatory adherence for global market access.

Alkem Laboratories reported a rise in third-quarter profit, supported by steady domestic formulations growth and improving operating efficiencies. In a parallel strategic move, the company announced the acquisition of a stake in Occlutech, a global medical device manufacturer, marking a significant step toward diversification beyond pharmaceuticals. The earnings uptick reflects disciplined cost management and resilient demand in key therapeutic segments. Meanwhile, the investment in Occlutech underscores Alkem’s intent to deepen its footprint in the high-value medtech space.

In a significant boost to India’s biopharmaceutical innovation landscape, Alkem Laboratories Ltd. has partnered with the Indian Institute of Technology (IIT) Bombay to establish a cutting-edge Immuno-Therapeutics and Research Centre. The collaboration aims to accelerate advancements in immunology, focusing on the development of next-generation therapies for autoimmune diseases, cancer, and infectious disorders.

Alkem Laboratories has announced the launch of a biosimilar therapy for breast cancer patients in India, marking a milestone in the country’s oncology treatment landscape. The drug, designed as a cost-effective alternative to an existing biologic, aims to improve accessibility and affordability for thousands of patients battling one of the most prevalent cancers among Indian women. With rising cancer incidence rates and escalating treatment costs, biosimilars are increasingly viewed as a critical solution to balance quality care with economic feasibility.

Alkem Laboratories Ltd. has posted a 22% year-on-year increase in net profit for the first quarter, reaching Rs. 664 crore, driven by robust performance in both domestic and international markets. Revenue growth was supported by strong demand across acute and chronic therapy segments, coupled with steady export momentum in the United States and emerging markets. Operational efficiencies, strategic product launches, and disciplined cost management further strengthened profitability.